NURR1 Involvement in Recombinant Tissue-Type Plasminogen Activator Treatment Complications After Ischemic Stroke | Zendy

Cristina Merino-Zamorano | Zendy; Mar HernándezGuillamón | Zendy; Amandine Jullienne | Zendy; Audrey Le Béhot | Zendy; Isabelle Bardou | Zendy; Mireia Parés | Zendy; Israel FernándezCadenas | Zendy; Dolors Giralt | Zendy; Caty Carrera | Zendy; Marc Ribó | Zendy; Denis Vivien | Zendy; Carine Ali | Zendy; Anna Rosell | Zendy; Joan Montaner | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

NURR1 Involvement in Recombinant Tissue-Type Plasminogen Activator Treatment Complications After Ischemic Stroke

Author(s) -

Cristina Merino-Zamorano,

Mar HernándezGuillamón,

Amandine Jullienne,

Audrey Le Béhot,

Isabelle Bardou,

Mireia Parés,

Israel FernándezCadenas,

Dolors Giralt,

Caty Carrera,

Marc Ribó,

Denis Vivien,

Carine Ali,

Anna Rosell,

Joan Montaner

Publication year - 2014

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.114.006826

Subject(s) - medicine , tissue plasminogen activator , thrombolysis , plasminogen activator , stroke (engine) , proinflammatory cytokine , endothelial dysfunction , immunology , inflammation , mechanical engineering , myocardial infarction , engineering

Despite the effectiveness of recombinant tissue-type plasminogen activator (r-tPA) during the acute phase of ischemic stroke, the therapy remains limited by a narrow time window and the occurrence of occasional vascular side effects, particularly symptomatic hemorrhages. Our aim was to investigate the mechanisms underlying the endothelial damage resulting from r-tPA treatment in ischemic-like conditions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research